
|Articles|June 1, 2001
Humanized antibody produces marked improvement in plaque psoriasis
Washington - The humanized monoclonal antibody efalizumab, given once weekly subcutaneously, produces profound clinical improvement in moderate to severe plaque psoriasis, reported Craig Leonardi, M.D., at the American Academy of Dermatology's 59th annual meeting.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Envudeucitinib Achieves 54% PASI 100 Rate at 48 Weeks in Phase 3 Extension
2
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
3
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
4
Biologic Therapies in AD and CSU: Progress and the Push for Precision Medicine
5











